Ace Therapeutics assists in drug development targeting H. pylori and provides drug delivery system development services for drugs such as H. pylori small molecules and therapeutic peptides and proteins. We provide these services to address low drug efficacy due to problems such as untargeted drug transport or short drug residence time.
H. pylori drugs will have better efficacy when released centrally in the stomach around H. pylori. Gastroretentive drug delivery systems (DDS) can successfully improve the residence time of drugs in the stomach. Among them, nano-DDS, such as polymeric nanoparticles, nanostructured lipid carriers, and nanoemulsions, are dominant in gastroretentive DDS. Various modifications of these nanoparticles (Fig. 1) can improve the properties of nanoparticles to achieve better delivery. In addition, pH-sensitive delivery systems are also available for H. pylori treatment.
Fig. 1 Nanoparticle modification for possible treatment of H. pylori.
Ace Therapeutics supports the development of DDS to treat H. pylori in various ways. We provide services for modification of nano-DDS, development of pH-sensitive DDS, and development of other DDS. In detail, our services can be divided into the following three aspects.
Development of DDS with increased ability in targeting H. pylori
Improving the ability of DDS in delivering drugs to H. pylori can improve treatment outcomes. We offer to develop DDS that increase the ability to target H. pylori in four directions. Based on the pH homeostasis mechanism of H. pylori, we provide to develop ureido-conjugated DDS. We also develop DDS that take advantage of the adhesive properties of H. pylori adhesins. In addition, we offer delivery system development based on signal peptides and antimicrobial peptides with a high affinity for H. pylori cell membranes.
Development of pH-sensitive DDS with increased therapeutic capabilities
Releasing the drug at the right time or in the right environment also contributes to the effectiveness of the treatment. For pH-sensitive DDS, we first offer to develop DDS that release drugs in a pH-neutral environment to improve the treatment capabilities of antibiotics. Then, we help develop DDS that act in an acidic environment to play an adjunctive therapeutic role.
Development of DDS with increased gastric retention capacity
We provide to develop gastroretentive delivery systems that make use of the ability of H. pylori to stay in the stomach and the adhesion of H. pylori drugs. These systems not only increase the drug duration in the stomach but also reduce H. pylori adhesion to the gastric mucosa and enhance the treatment of H. pylori. What's more, we offer to develop probiotic-based DDS to improve the retention of therapeutic proteins and peptides in the stomach.
Our Advantages
We have all-in-one nano-delivery system production equipment and high-end nano-delivery system testing equipment.
Our professional nano-delivery system modification experts and H. pylori research experts collaborate to develop H. pylori-specific DDS. We are more specialized and more targeted.
Cooperate with us
Ace Therapeutics is your reliable partner for the development of DDS for H. pylori drugs. We are experts in drug delivery system development and we also take full advantage of the characteristics of H. pylori during the development of DDS. Let's cooperate with each other to develop DDS for H. pylori drugs.
References
- Mahor, A.; Gupta, R. Recent advances in gastro retentive drug delivery systems and its application on treatment of H. pylori infections. Journal of Analytical & Pharmaceutical Research. 2018, 7(4): 404‒10.
- De Souza, M. P. C.; et al. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections. Critical Reviews in Microbiology. 2021, 47(4): 435-60.
- Osman, N.; et al. Surface modification of nano-drug delivery systems for enhancing antibiotic delivery and activity. WIREs Nanomedicine and Nanobiotechnology. 2022, 14(1): e1758.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
